Avelumab not checked

EMD Serono Research & Development Institute, Inc. · MSB0010718C · Anti PD-L1

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
21 active
38 in total · 27 in the EU
Targets
 

What this is

How it works
Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells.Programmed Death Ligand-1 Blocker FDA class
How it’s given
“Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).”In the company’s words, NCT03815643 on ClinicalTrials.gov
Tested for
Solid Tumors, Locally Advanced or Metastatic Urothelial Carcinoma
Main trialPhase 3
“The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.”In the company’s words, NCT03815643 on ClinicalTrials.gov
Other names
MSB0010718C · Anti PD-L1

Other drugs for Solid Tumors

All 2438 drugs for Solid Tumors

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials38

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 24 Nov 2026 Avelumab Program Rollover Study
Phase 2Active, not recruiting 20 Jun 2025 A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
Phase 3Completed 13 Sep 2019 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
Phase 3Completed 6 Dec 2021 Avelumab in First-line NSCLC (JAVELIN Lung 100)
Phase 2Completed 2 May 2019 Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Phase 2Completed 30 Sep 2020 Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
Phase 2Withdrawn 12 Jan 2026 Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
Phase 1Completed 29 Jul 2019 Phase I/Ib Multiple Ascending Dose Study in China
Phase 1Completed 16 Dec 2019 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Phase 1Terminated 8 Oct 2020 A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)
Phase 1Terminated 27 Jul 2021 Phase I/II Study of Avelumab in Pediatric Cancer Participants
Phase 1Completed 1 Sep 2021 Study of Avelumab-M3814 Combinations
Phase 1Terminated 11 Feb 2026 Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
Phase 1Completed 14 Jul 2026 Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
Phase 2Authorised not given Immunological variables associated to ICI toxicity in cancer patients
Phase 1/2Authorised not given REGOMUNE : A phase I/II study of Regorafenib plus Avelumab in solid tumors
Phase 2Authorised not given A phase II study of Taxane-Platinum based chemotherapy with cetuximab followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN).
Phase 2Authorised not given A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients with PD-L1 combined positive score (CPS)≥1≤19: the immunotherapy.
Phase 3/4Authorised not given Avelumab Short Maintenance Trial
Phase 2Ended not given A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3)
Phase 3Authorised not given MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
Phase 3Authorised not given A Phase III randomized trial of avelumab-cetuximab- Radiotherapy versus standards of care in locally advanced squamous cell carcinoma of the head and neck (REACH)
Phase 3Ended not given A–BRAVE-Trial. ADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS WITH THE ANTI-PD-L1 ANTIBODY AVELUMAB: A PHASE III RANDOMIZED TRIAL
Phase 1/2Authorised not given AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 2Authorised not given PULSE : Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including a platinum salt in patients suffering from locally advanced or metastatic squamous cell penile carcinoma (SPC)
Phase 2Authorised not given Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence (N17JAV)
Phase 2Authorised not given CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVING A DEEP MOLECULAR RESPONSE: AN ADAPTIVE TRIAL BASED ON A DROP LOSER DESIGN - ACTIW STUDY
Phase 4Authorised not given PROSPECTIVE EVALUATION OF THE DDR GENES ALTERATION TO PREDICT RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED UROTHELIAL CANCER
Phase 2Authorised not given Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Moneo trial
Phase 2Authorised not given CHemotherapy And Sequential ImmunoTherapy for locally advanced urothelial cancer: the CHASIT study
Phase 2Ended not given PRODIGE 54 SAMCO : MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI)
Phase 2Authorised not given DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
Phase 3Not authorised not given Evaluation of the efficacy and safety of the combination of platinum-based chemotherapy (Gemcitabin/Cisplatin) and immunotherapy compared with platinum-based chemotherapy alone in neoadjuvant setting before surgery of high-grade localized upper tract urothelial carcinoma (UTUC).
Phase 2Ended not given A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST
Phase 2Authorised not given A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients
Phase 2Authorised not given DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for advanced and metastatic penile carcinoma
Phase 2Authorised not given A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and Docetaxel in Patients with Recurrent Metastatic Head and Neck Cancer - AVETUX-HN
Phase 2Authorised not given Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Avelumab

Following is part of Solo: you see every change to Avelumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in